Bayers, Stroke

Bayer's Stroke Rollout and China Cancer Nod Cap a Landmark Fortnight for Pharma

Published on 11/17/2026 at 08:51 | Editorial boerse-global.de
Bayer plans a US launch of Sunharbo, the first approved factor XIa inhibitor, after FDA clearance, and raised 2026 guidance on pharma strength.
Bayers, Stroke, Rollout, China, Cancer, Nod, Cap, Landmark, Fortnight, Pharma Illustration mit AI erstellt.

Bayer is preparing to ship its newly approved stroke-prevention drug in the United States between mid and late November, the company expects, following last week's green light from the US Food and Drug Administration. The medicine, marketed as Sunharbo and based on the active ingredient asundexian, is the world's first approved factor XIa inhibitor, according to the regulator.

The FDA cleared it to cut stroke risk in adults who have recently suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. The approved regimen is a 50 mg dose given alongside an antiplatelet therapy, and the filing rested on the Phase 3 OCEANIC-STROKE trial.

China Clears a Lung Cancer Drug

The stroke approval is only half of a busy run for Bayer's pharmaceutical division. On 4 November the company reported that China had approved sevabertinib as a first-line treatment for adults with unresectable, locally advanced or metastatic HER2-mutant non-small cell lung cancer — a clearance that explicitly covers use at the very start of therapy.

Together, the two decisions give the German group fresh commercial launches on two continents within a matter of days, reinforcing the pharma unit that has become the main engine behind its upgraded financial targets.

Should investors sell immediately? Or is it worth buying Bayer?

Guidance Raised on Pharma Strength

Bayer lifted its full-year outlook roughly two weeks ago, citing the performance of its drug business. The group now expects EBITDA before special items of EUR 9.8 billion to EUR 10.3 billion for 2026, up from its previous forecast. It also raised its margin expectations for the Pharmaceuticals division and its guidance for free cash flow. Handelsblatt attributed the share-price gain at the time to the strong pharma business and the improved outlook.

That upgrade followed third-quarter 2026 results showing group revenue of EUR 10.1 billion and EBITDA before special items of EUR 1.62 billion.

Deutsche Bank Turns More Bullish

Deutsche Bank Research responded last week by raising its price target on Bayer from EUR 60 to EUR 65 while reaffirming its buy rating, according to media reports. Analyst Virginie Boucher-Ferte also lifted her estimates for EBITDA and earnings per share for 2027 and 2028, dpa-AFX reported.

Bayer at a turning point? This analysis reveals what investors need to know now.

Roundup Litigation Still in Play

Away from the pipeline, a US federal judge was reported yesterday to be examining which Roundup claims can proceed following a Supreme Court ruling. The review concerns the legal position surrounding Monsanto's glyphosate-based herbicide, keeping the focus on how individual cases will continue after the court's decision.

Ad

Bayer Stock: New Analysis - 17 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYERS | boerse | 70525483 |